Supernus Pharmaceuticals, Inc.
SUPN
$50.53
$1.162.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.29% | 8.63% | 4.54% | 5.55% | 11.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.29% | 8.63% | 4.54% | 5.55% | 11.82% |
| Cost of Revenue | 10.40% | 17.03% | 61.83% | 119.03% | 111.37% |
| Gross Profit | 18.18% | 6.47% | -5.90% | -9.42% | -2.83% |
| SG&A Expenses | 33.09% | 26.55% | 13.89% | 4.56% | 1.73% |
| Depreciation & Amortization | 22.79% | 14.72% | 2.94% | -5.11% | -5.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.65% | 15.77% | 9.93% | 4.00% | 2.89% |
| Operating Income | -59.48% | -60.56% | -47.49% | 28.05% | 950.62% |
| Income Before Tax | -153.54% | -150.10% | -128.61% | 119.55% | 1,628.66% |
| Income Tax Expenses | -167.38% | -143.66% | -112.67% | -45.11% | 214.45% |
| Earnings from Continuing Operations | -146.87% | -152.19% | -132.02% | 1,131.09% | 499.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.87% | -152.19% | -132.02% | 1,131.09% | 499.24% |
| EBIT | -59.48% | -60.56% | -47.49% | 28.05% | 950.62% |
| EBITDA | -12.86% | -18.50% | -18.65% | 5.64% | 53.54% |
| EPS Basic | -145.12% | -150.75% | -130.58% | 1,146.57% | 496.09% |
| Normalized Basic EPS | -54.44% | -52.48% | -36.12% | 34.41% | 472.96% |
| EPS Diluted | -146.19% | -151.70% | -131.88% | 1,219.17% | 478.63% |
| Normalized Diluted EPS | -53.92% | -51.95% | -36.04% | 33.64% | 474.02% |
| Average Basic Shares Outstanding | 2.76% | 2.45% | 1.97% | 1.58% | 1.33% |
| Average Diluted Shares Outstanding | 1.84% | 1.15% | 1.28% | 1.68% | 1.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |